uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Variations in Quality and Outcomes of Warfarin Therapy in New Zealand
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmaceutical Biosciences.
2015 (English)Independent thesis Advanced level (degree of Master (One Year)), 20 credits / 30 HE creditsStudent thesis
Abstract [en]

Introduction:  Despite the recent introduction of new agents, warfarin remains the most commonly prescribed oral anticoagulant and is used for a variety of cardiovascular and thromboembolic diseases. Warfarin has a narrow therapeutic range. It demonstrates intra- and inter-individual variation in dose response, and is affected by a number of significant interactions. While above range patients are at risk of bleeding, conversely when below range they are not protected against thromboembolic events. The quality of care can be estimated by measuring the proportion of time the patient spends in the therapeutic range (TTR). Aims: To evaluate quality of warfarin treatment in Auckland, New Zealand, using TTR and to find variations of TTR and associations between TTR and clinical outcomes, this to explore possible health inequalities regarding anticoagulation control. Materials and Methods: Patients prescribed warfarin were identified from pharmacy claims data. A number of demographic, laboratory and hospitalisations data were extracted from health databases and linked for analysis. Patient TTRs were calculated using the Rosendaal method. Linear regressions models were developed to find associations between demographics. Cox proportional hazard models were used to evaluate the relationship between TTR and clinical outcomes. Results: The population had a mean TTR of 55.3%. Multivariable regression model showed 4.1% of the variance of TTR to be due to ethnicity, deprivation and age (p<0.05). Increasing TTR indicated less risk of thromboembolic and bleeding events. Conclusions: As expected low quality of treatment is associated with higher risk of adverse events with warfarin. Differences occur between patients in the quality of warfarin. Further research is needed to describe quality of care, and to identify improve patient outcomes.

Place, publisher, year, edition, pages
2015. , 37 p.
Keyword [en]
Warfarin, anticoagulation, New Zealand, Auckland
National Category
Social and Clinical Pharmacy
Identifiers
URN: urn:nbn:se:uu:diva-260679OAI: oai:DiVA.org:uu-260679DiVA: diva2:847972
Subject / course
Pharmaceutical Biosciences
Educational program
Master of Science Programme in Pharmacy
Supervisors
Examiners
Available from: 2015-08-25 Created: 2015-08-22 Last updated: 2015-08-25Bibliographically approved

Open Access in DiVA

No full text

By organisation
Department of Pharmaceutical Biosciences
Social and Clinical Pharmacy

Search outside of DiVA

GoogleGoogle Scholar

urn-nbn

Altmetric score

urn-nbn
Total: 365 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf